secwatch.observer — SEC 8-K summary
======================================

Issuer:     AtriCure, Inc. (ATRC)
CIK:        0001323885
Form:       8-K
Filed at:   2022-01-10T23:59:59+00:00
Accession:  0001323885-22-000003
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AtriCure reports preliminary Q4 revenue $73.2M (+27% YoY), guides FY2022 $315-330M
--------------------------------------------------------------------------------

- Q4 2021 revenue ~$73.2M (+27% YoY); U.S. $61.2M (+29%), Intl $12.0M (+16% as reported).
- Full year 2021 revenue $274.3M (+33% YoY); adj. EBITDA loss ~$10M, adj. loss per share ~$1.20.
- Management guides FY2022 revenue $315-330M (15-20% growth over 2021), subject to pandemic uncertainty.
- Preliminary, unaudited results – final audited results with GAAP reconciliation to follow in later release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1323885/000132388522000003/0001323885-22-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1323885/000132388522000003/atrc-20220110.htm
  HTML page:      https://secwatch.observer/filing/0001323885-22-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer